冠状动脉药物洗脱支架的特点及其临床安全性

Characteristics and clinical security of coronary artery drug-eluting stent

尽管随着冠状动脉支架设计工艺与技术的改善,金属裸支架的再狭窄发生率已降至15%左右,但仍成为制约冠状动脉粥样硬化性心脏病介入治疗远期疗效的最大瓶颈。药物洗脱支架是近年来问世的新颖支架,在预防术后再狭窄的发生方面展示了美好的前景。虽然药物洗脱支架的临床结果令人鼓舞,但是适应证还是相对单一,一些相关问题还未解决。那么药物洗脱支架究竟面临着怎样的问题?应该怎样认识这些问题?文章的中心思想是比较冠状动脉粥样硬化性心脏病患者采用药物洗脱支架和金属裸支架治疗的安全性,分析影响药物洗脱支架安全性的主要因素以及其面临的问题,探讨药物洗脱支架的未来发展方向。

Technology and technique of coronary artery stent have been developed to a certain degree, restenosis rate of metal stent reduces to 15%, but coronary artery stent is still difficult for long-term effect of interventional therapy on coronary atherosclerotic heart disease. Drug-eluting stent is newly discovered during recent years, while it is prospect for preventing restenosis postoperatively. Although clinical efficacy of drug-eluting stent is encouraged, indication is still simple. In addition, some events related to drug-eluting stent remain poorly unknown. This study was designed to compare security between drug-eluting stent and metal bared stent, analyze major factors correlated with security of drug-eluting stent, and investigate the development of drug-eluting stent.